Wedbush Remains Bullish on MannKind Corporation (MNKD)

MannKind Corporation (NASDAQ:MNKD) is one of the best biotech penny stocks to buy right now. Analyst Yun Zhong from Wedbush maintained a Buy rating on MannKind Corporation (NASDAQ:MNKD) on June 27, setting an $11.00 price target.

Is MannKind Corporation (MNKD) the Best Cancer Stock to Invest in for Long-Term Gain?

A close-up of a doctor’s hand pressing on an inhaler, conveying the effect of the company’s therapeutic products.

The analyst based the rating on MannKind Corporation’s (NASDAQ:MNKD) innovative inhaled insulin product, Afrezza, stating that it represents a considerably undervalued opportunity in the diabetes treatment market.

Clinical data from the Phase 3 INHALE-1 and INHALE-3 studies support Afrezza’s potential in both the adult and pediatric population. The data also highlights the product’s fit in the current treatment paradigm, positioning it as an ultra-rapid acting insulin option that may boost market adoption.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that develops and commercializes innovative therapeutic devices and products that address serious unmet medical needs for endocrine and orphan lung diseases.

The company’s pipeline and products include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

While we acknowledge the potential of MNKD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MNKD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.